IDEA Collider: Innovation & Asymmetric Learning in Pharma Biotech Innovations and AI in Drug Development with Alex Telford:
Sep 23, 2025
In a captivating discussion, Alex Telford, a biotech founder and co-founder of Convoke Bio, shares insights from his journey in drug development. He explores how AI and language models can revolutionize pharmaceutical workflows, tackling inefficiencies in clinical practices. Telford highlights the significance of data management and the role of emerging AI technologies in drug discovery. He also delves into China’s growing influence in biotech and the challenges of understanding neuroscience. Expect a thought-provoking conversation on the future of biopharma!
AI Snips
Chapters
Books
Transcript
Episode notes
Don’t Automate Bad Processes; Redesign Them
- Alex warns against automating existing suboptimal processes and locking them in with AI.
- He expects organizational flattening where decision-makers directly interact with data via models.
Everyone Launches Drugs At A Similar Pace
- Alex notes the curious empirical pattern that most pharma firms launch drugs at similar rates despite different cultures and platforms.
- He questions whether drug development performance is constrained by fundamental biological or structural limits rather than superior firm capabilities.
Slow Feedback Limits Pharma Learning
- Long cycle times and diluted market signals make learning and rapid iteration in pharma far harder than in software.
- Shortening feedback loops is essential to increase variance in company performance and faster learning.
